Preliminary findings from the REQUEST registry study were presented at the 3rd International Coronary Conference, ICC, in New York, USA, this weekend.
The REQUEST study is a prospective, multicenter registry with leading cardiac surgery centers from Europe, USA and Canada, led by Coordinating Investigator Professor David Taggart from the University of Oxford. The objective is to study how often the combination of high-resolution ultrasound imaging and transit time flow measurements (TTFM) performed with Medistim’s VeriQC or MiraQ devices will change the surgical procedure. The surgical coronary artery bypass grafting (CABG) protocol includes ultrasound scanning of the aorta, conduit, target coronary vessel and anastomosis as well as TTFM graft assessment. The study is unique, since data from such a protocol have never been collected before.
The hypothesis motivating the REQUEST registry study is that employing this combination of functional flow measurement and morphological ultrasound imaging data will enable surgeons to make better-informed decisions during coronary surgery, and thereby improve surgical quality, outcomes and ultimately, contribute to improved healthcare efficiency from this surgical procedure.
The endpoints for the study are any change in planned surgical procedure, type of procedure adaptation, number of graft revisions and adverse events.
Professor Taggart presented the first preliminary results from the 776 patients included so far showing that 26% of the patient population had one or more surgical changes made to the procedure based on imaging and flow data. “This is a high number, which indicates that the addition of high-resolution ultrasound imaging is indeed helpful in guiding the CABG procedure, even for highly experienced surgeons”, says Professor Taggart. “It will be of considerable interest to evaluate the data from the full 1000 patient population and learn more about how the imaging and flow techniques can help guide CABG surgery during the various stages of the procedure.”
“We believe this is a very significant number of changes, that speaks to the value of adding imaging to flow measurements during CABG surgical planning and graft assessment”, says Medistim CEO Kari E. Krogstad. “The study is progressing well and we look forward to analyzing the final data set.”
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Medistim was established in 1984, and has a track record of profitable growth over the past >10 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the US, Germany,